An increasing body of evidence in the medical literature overwhelmingly supports clinically significant variability in the effect of ASA , which has been well-established in findings from recent trials, including the Heart Outcomes Prevention Evaluation (HOPE) Study and the CHARISMA trial. These trials have demonstrated that:
ASA is the abbreviation for Acetylsalicylic Acid
*In Canada, Aspirin is a trademark of Bayer AG, used under license.
*Entrophen is a Registered trademark of PendoPharm.
*ASA Effect and its logo are trademarks of Bescot Healthcare Canada Inc.
- Though resistance may not be the correct term to describe this phenomenon, not all patients receive the same protective benefits from low-dose ASA therapy.
- Increased levels of urinary 11dhTxB2 are associated with as much as a four fold increased risk for adverse cardiovascular events or death.
- Statin treatment is associated with lower concentrations of 11dhTxB2.
- 11dhTxB2 is an independent, modifiable predictor of risk for stroke, heart attack and cardiac death.